옵션 체인은 다양한 행사가격과 만기일에 대한 Genmab의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Genmab에 대한 시장 심리를 평가합니다..

Genmab (NASDAQ:GMAB) 주식, 옵션 체인

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Coinbase Photo by Useacoin on Shutterstock

Equities

Large Cap

News

Movers

Trading Ideas

AAPL

ADBE

COIN

EXPE

GMAB

HOOD

IBKR

SAIL

이들 대형 주식은 지난주에 최악의 성과를 보였다. 이 주식이 당신의 포트폴리오에 있나요? 1. 테라다인(NASDAQ:TER)의 주가가 20.08% 하락했다. 이 회사는 포토닉 IC 테스트 회사인 퀀티파이 포토닉스(Quantifi Photonics)를 비공개 금액에 인수하기로 합의했다. 애널리스트들은 이 회사의 가격 전망을 하향 조정했다.

코인베이스, 애플, 로빈후드 등 지난주 급락한 대형주 12종목 (3월 10일-3월 14일)

Genmab AS

Barclays analyst Lauren Lieberman downgrades PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) from Overweight to Equal-Weight and lowers the price target from $168 to $156.

Downgrades

Price Target

Analyst Ratings

Barclays Downgrades PepsiCo to Equal-Weight, Lowers Price Target to $156

General

LASE

Laser Photonics Enhances Gantry Laser Technology In Partnership With Subsidiary Control Micro Systems

Mizuho analyst Maheep Mandloi initiates coverage on Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Neutral rating and announces Price Target of $28.

Initiation

Mizuho Initiates Coverage On Bloom Energy with Neutral Rating, Announces Price Target of $28

OneConnect Financial Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OCFT#NYSE">OCFT</a>) reported quarterly losses of $(2.18) per share. This is a 600.96 percent decrease over losses of $(0.31) per share from the same period last year. The company reported $57.78 million in sales this quarter. This is a 54.97 percent decrease over sales of $128.31 million the same period last year.

Earnings

OCFT

OneConnect Financial Tech Q4 EPS $(2.18) Down From $(0.31) YoY, Sales $57.78M Down From $128.31M YoY

Jefferies analyst Edison Lee upgrades GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) from Hold to Buy and announces $45 price target.

Upgrades

Jefferies Upgrades GDS Holdings to Buy, Announces $45 Price Target

Jefferies analyst Julien Dumoulin-Smith downgrades TPI Composites (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) from Hold to Underperform and lowers the price target from $2.3 to $0.5.

TPIC

Jefferies Downgrades TPI Composites to Underperform, Lowers Price Target to $0.5

TIGR: 8% &#x7C; <a href="https://www.benzinga.com//node/44371198">UP Fintech Holding Q4 Adj $0.17 Beats $0.11 Estimate, Sales $124.10M Beat $97.00M Estimate</a>
&nbsp;
RL: 3% &#x7C; <a href="https://www.benzinga.com//node/44373413">Ralph Lauren shares are trading higher after Goldman Sachs upgraded the stock from Neutral to Buy and raised its price target from $280 to $286.</a>
&nbsp;
BBAI: -9% &#x7C; <a href="https://www.benzinga.com//node/44373404">BigBear.ai shares are trading lower after the company said it identified the need to restate certain prior financial statements.</a>

BBAI

TIGR

Market-Moving News for March 18th

DPRO

Draganfly Completes Demonstration For Simulated Delivery Of Medical Supplies With Massachusetts Department of Transportation

HC Wainwright &amp; Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKUR#NASDAQ">OKUR</a>) with a Buy and lowers the price target from $40 to $34.

OKUR

HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $34

Tech

VERI

Veritone's AI solutions And Software Added To Carahsoft Canada's Supply Arrangement For SaaS Government of Canada Method Of Supply

Evercore ISI Group analyst Amit Daryanani maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Outperform and raises the price target from $260 to $275.

Evercore ISI Group Maintains Outperform on Apple, Raises Price Target to $275

WIIM

Tencent Music shares are trading higher after the company reported better-than-expected Q4 sales.

Ralph Lauren shares are trading higher after Goldman Sachs upgraded the stock from Neutral to Buy and raised its price target from $280 to $286.

BigBear.ai shares are trading lower after the company said it identified the need to restate certain prior financial statements.

NWTG

Newton Golf Launches New Corporate and Investor Relations Website

RDHL

RedHill Biopharma Plans To Submit FDA Approved Talicia Used To Treat H. Pylori Infection For UK Marketing Approval

Biotech

Health Care

PRME

Prime Medicine Unveiled A Preclinical Program For The Treatment Of Alpha-1 Antitrypsin Deficiency, The Next Program Within Its Liver Franchise. Prime Medicine Expects To File An Investigational New Drug And/Or Clinical Trial Application In Mid-2026

TLRY

Tilray Brands Company Manitoba Harvest Expands Into Functional Snacking With New Superseed Snack Clusters

BABA

RYDE

Ryde Assimilates Alipay To Boost Payment Experience For International Visitors In Singapore

Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.52) by 42.76 percent. This is a 24.35 percent increase over losses of $(1.15) per share from the same period last year.

ACXP

Acurx Pharmaceuticals FY 2024 GAAP EPS $(0.87) Beats $(1.52) Estimate

Press Releases

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab Publishes 2024 Annual Report

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Comments

Genmab

Genmab (GMAB) 옵션

Genmab (NASDAQ:GMAB) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌